Gilead Sciences, Inc. (GILD)
| Market Cap | 166.66B +17.4% |
| Revenue (ttm) | 29.44B +2.4% |
| Net Income | 8.51B +1,672.9% |
| EPS | 6.78 +1,684.2% |
| Shares Out | 1.24B |
| PE Ratio | 19.80 |
| Forward PE | 15.49 |
| Dividend | $3.28 (2.44%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 4,066,710 |
| Open | 136.85 |
| Previous Close | 136.88 |
| Day's Range | 134.10 - 137.47 |
| 52-Week Range | 93.37 - 157.29 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 146.50 (+9.13%) |
| Earnings Date | Apr 23, 2026 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for GILD stock is "Strong Buy." The 12-month stock price target is $146.5, which is an increase of 9.13% from the latest price.
News
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.
Gilead plans to develop Ouro's lead drug candidate, gamgertamig, alongside a Belgian pharma company.
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
Gilead said the deal would bolster its growing inflammation portfolio.
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal
Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth up to $2.18 billion.
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology ...
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports
Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2 billion, the Financial Times reported on Monday, citing people familiar with the matter.
5 Stocks to Buy in a High-Risk Bull Market
From Big Tech to overlooked value plays, Victoria Fernandez shares 5 stocks to own in a “high-risk bull market”—and where she sees opportunity despite rising risks.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
South Africa seeks local production of Gilead's HIV prevention drug
South Africa is asking local drugmakers to start a process to make Gilead Sciences' long-acting HIV prevention drug, lenacapavir, domestically, in a push to bring production to the region where it i...
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
FOSTER CITY, Calif.--(BUSINESS WIRE)--GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US.
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica...
Johanna Mercier on Gilead's HIV prevention innovation
Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, discusses Gilead's groundbreaking HIV prevention innovation — a twice-yearly injection with 99.9% efficacy during this...
Gilead's experimental HIV treatment shows low discontinuation rates in studies
Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low discontinuation rates, positioning the single-tablet regimen as a potential option ...
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treat...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca...
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't ...
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer tr...
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with ...
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.
Gilead Sciences is paying an 80% premium to Friday's closing price.
Gilead to acquire Arcellx for $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for ...
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: AC...